PL和PC方案治疗晚期非小细胞肺癌的疗效观察  

A Comparative Study Of Paclitaxel Plus Oxaliplatin Regimen and PaclitaxelPlus Cisplatin Regimen for Advanced Non-small-cell Lung Cancer

作　　者：韩守恒[1] 戴文香[1] 伍尤华[1] 

机构地区：[1]南华大学第一附属医院肿瘤内科,湖南衡阳421001

出　　处：《南华大学学报（医学版）》2007年第3期368-370,376,共4页Journal of Nanhua University(Medical Edition)

摘　　要：目的观察和比较紫杉醇联合草酸铂(PL)与联合顺铂(PC)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的初步疗效和患者的耐受性。方法42例晚期非小细胞肺癌患者,分别接受PL方案或PC方案治疗,PL组21例,PC组21例。结果两组均有20例可以评价疗效。PL组完全缓解1例,部分缓解6例,有效率为35.0%,PC组完全缓解0例,部分缓解6例,有效率为30.00%,PL组中位无进展时间为4.2月,PC组中位无进展时间为4.7月。PL组中位生存期8.8月;PC组中位生存期9.2月。结论PL方案和PC方案治疗晚期非小细胞肺癌疗效相似,但PL方案比PC方案的耐受性要好。Objective To observe and compare the efficacy and toxicity of Paclitaxel plus Oxaliplatin regimen and paclitaxel plus cisplatin regimen in the treatment of the cases with advanced non - small - cell lung cancer. Methods The total of 42 cases were enrolled in the investigation, 21 cases received PL regimen and 21 cases received PC regimen. Two groups were well - matched with baseline disease characteristics （ P 〉 0.05 ）. Result 20 cases can be evaluated in PL and PC regimens respectively. In PL group, the response rate was 35.0% （7/20）, 1 achieved complete response （CR） ; In PC group, the response rate was 30.00% （6/20）, 0 achieved complete response （CR）. The median time - to - progression was 4.2 months for PL group and 4.7 months for PC group. In PL group, the median survival was 8.8 months; In PC group, the median survival was 9.2 months. The major toxic reactions in the two groups were marrow depression, gastrointestinal reaction, renal toxicity and neurotoxicity. Conclusions The efficacy of PL regimen and PC regimen in the treatment of advanced non - small cell lung cancer was similar, but PL regimen would be better tolerated than PC regimen.

关 键 词：非小细胞肺癌 紫杉醇 草酸铂 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]